Blas Gil-Extremera
Overview
Explore the profile of Blas Gil-Extremera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchez-Rodriguez E, Biel-Glesson S, Fernandez-Navarro J, Calleja M, Espejo-Calvo J, Gil-Extremera B, et al.
Nutrients
. 2019 Mar;
11(3).
PMID: 30845690
A regular consumption of virgin olive oil (VOO) is associated with a reduced risk of cardiovascular disease. We aimed to assess whether the raw intake of an optimized VOO (OVOO,...
2.
Sanchez-Rodriguez E, Lima-Cabello E, Biel-Glesson S, Fernandez-Navarro J, Calleja M, Roca M, et al.
Nutrients
. 2018 May;
10(5).
PMID: 29772657
The aim of this study was to evaluate the effect of virgin olive oils (VOOs) enriched with phenolic compounds and triterpenes on metabolic syndrome and endothelial function biomarkers in healthy...
3.
McKie E, Reid J, Mistry P, DeWall S, Abberley L, Ambery P, et al.
PLoS One
. 2016 Mar;
11(3):e0150018.
PMID: 26930607
Objective: Evidence suggests that chronic subclinical inflammation plays an important role in the pathogenesis of type 2 diabetes (T2DM). Circulating levels of interleukin (IL)-18 appear to be associated with a...
4.
Kjeldsen S, Sica D, Haller H, Cha G, Gil-Extremera B, Harvey P, et al.
J Hypertens
. 2014 Aug;
32(12):2488-98.
PMID: 25144296
Objectives: DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) aimed to determine the dose-response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with...
5.
Gil-Extremera B, Tuomilehto J, Cia-Gomez P
Int J Hypertens
. 2012 Apr;
2012:610525.
PMID: 22518288
No abstract available.
6.
Gil-Extremera B
Int J Hypertens
. 2012 Jan;
2012:684515.
PMID: 22254131
Lipid disorders are a common clinical challenge in the western countries. In patients with dyslipemia (total cholesterol > 200 mg/dl, HDL cholesterol < 35 mg/dl, LDL cholesterol > 130 mg/dl...
7.
Gil-Extremera B, Cia-Gomez P
Int J Hypertens
. 2011 Aug;
2012:859176.
PMID: 21876789
Background. The incidence of hypertension in the Western countries is continuously increasing in the elderly population and remains the leading cause of cardiovascular and morbidity. Methods. we analysed some significant...
8.
Peters R, Beckett N, Burch L, de Vernejoul M, Liu L, Duggan J, et al.
Age Ageing
. 2010 Jun;
39(5):609-16.
PMID: 20573778
Background: fractures may have serious implications in an elderly individual, and fracture prevention may include a careful choice of medications. Design: the Hypertension in the Very Elderly Trial (HYVET) was...
9.
Gil-Extremera B, Mendez G, Zakson M, Meehan A, Shah A, Lin J, et al.
Metab Syndr Relat Disord
. 2008 Mar;
5(4):305-14.
PMID: 18370800
Background: We compared the lipid-altering effects of ezetimibe/simvastatin (EZE/SIMVA) co-administered with fenofibrate (FENO) in mixed hyperlipidemic patients with (MetS) versus those without MetS. Methods: A total of 611 patients, 20...
10.
Farnier M, Roth E, Gil-Extremera B, Mendez G, Macdonell G, Hamlin C, et al.
Am Heart J
. 2007 Jan;
153(2):335.e1-8.
PMID: 17239698
Background: Mixed hyperlipidemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and TG-rich lipoprotein levels. Methods: In a multicenter, randomized, double-blind, placebo-controlled, parallel arm trial, eligible patients were...